Thomas N. Kakuda

4.3k total citations
109 papers, 3.1k citations indexed

About

Thomas N. Kakuda is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Thomas N. Kakuda has authored 109 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Infectious Diseases, 44 papers in Virology and 42 papers in Epidemiology. Recurrent topics in Thomas N. Kakuda's work include HIV/AIDS drug development and treatment (79 papers), HIV Research and Treatment (44 papers) and Hepatitis C virus research (35 papers). Thomas N. Kakuda is often cited by papers focused on HIV/AIDS drug development and treatment (79 papers), HIV Research and Treatment (44 papers) and Hepatitis C virus research (35 papers). Thomas N. Kakuda collaborates with scholars based in United States, Belgium and United Kingdom. Thomas N. Kakuda's co-authors include Peter L. Anderson, Richard M. W. Hoetelmans, Courtney V. Fletcher, Monika Schöller‐Gyüre, Richard C. Brundage, Goedele De Smedt, Kees Brinkman, Brian Woodfall, Monika Peeters and Jennifer J. Kiser and has published in prestigious journals such as Gastroenterology, PLoS ONE and Hepatology.

In The Last Decade

Thomas N. Kakuda

104 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas N. Kakuda United States 29 2.3k 1.5k 889 620 428 109 3.1k
Jennifer J. Kiser United States 32 2.5k 1.1× 1.1k 0.7× 1.3k 1.4× 403 0.7× 585 1.4× 107 3.5k
Brian P. Kearney United States 40 3.9k 1.7× 2.4k 1.6× 1.1k 1.3× 843 1.4× 698 1.6× 93 5.1k
Sherene Min United States 24 3.1k 1.3× 2.3k 1.5× 556 0.6× 654 1.1× 209 0.5× 46 3.3k
Peter P. Koopmans Netherlands 24 1.5k 0.7× 1.1k 0.7× 579 0.7× 731 1.2× 145 0.3× 54 2.5k
Ivy Song United States 23 1.7k 0.8× 1.1k 0.7× 487 0.5× 295 0.5× 148 0.3× 52 2.1k
Peter Ruane United States 32 3.4k 1.5× 2.2k 1.4× 1.7k 1.9× 745 1.2× 940 2.2× 78 4.7k
Rolf P. G. van Heeswijk Netherlands 24 1.9k 0.8× 750 0.5× 846 1.0× 202 0.3× 217 0.5× 41 2.3k
Daniel Podzamczer Spain 29 3.3k 1.4× 2.4k 1.6× 726 0.8× 1.5k 2.4× 185 0.4× 144 4.0k
Pieter L. Meenhorst Netherlands 29 1.7k 0.7× 1.3k 0.9× 567 0.6× 349 0.6× 148 0.3× 51 2.3k
Anne‐Marie Taburet France 26 1.5k 0.6× 818 0.5× 406 0.5× 271 0.4× 137 0.3× 74 2.1k

Countries citing papers authored by Thomas N. Kakuda

Since Specialization
Citations

This map shows the geographic impact of Thomas N. Kakuda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas N. Kakuda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas N. Kakuda more than expected).

Fields of papers citing papers by Thomas N. Kakuda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas N. Kakuda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas N. Kakuda. The network helps show where Thomas N. Kakuda may publish in the future.

Co-authorship network of co-authors of Thomas N. Kakuda

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas N. Kakuda. A scholar is included among the top collaborators of Thomas N. Kakuda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas N. Kakuda. Thomas N. Kakuda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Gane, Edward, Ewa Janczewska, Tetsuo Takehara, et al.. (2025). Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study. JHEP Reports. 7(10). 101516–101516. 1 indexed citations
3.
4.
Kakuda, Thomas N., Annemie Buelens, Ariane Kahnt, et al.. (2025). Pharmacokinetics, Safety, and Tolerability of Different Maintenance Dose Regimens of Mosnodenvir (JNJ‐1802) in Healthy Adult Participants. Clinical Pharmacology in Drug Development. 14(12). 960–970.
5.
Agarwal, Kosh, Marı́a Buti, Florian van Bömmel, et al.. (2024). JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2. Journal of Hepatology. 81(3). 404–414. 22 indexed citations
6.
7.
Yuen, Man‐Fung, Edward Gane, Dong Joon Kim, et al.. (2019). Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. Gastroenterology. 156(5). 1392–1403.e7. 117 indexed citations
8.
Flynn, Patricia M., Stéphane Blanche, Carlo Giaquinto, et al.. (2014). Efficacy and Safety of Darunavir/Ritonavir at 48 Weeks in Treatment-naïve, HIV-1–infected Adolescents. The Pediatric Infectious Disease Journal. 33(9). 940–945. 20 indexed citations
9.
Tudor‐Williams, Gareth, Pedro Cahn, Kulkanya Chokephaibulkit, et al.. (2014). Etravirine in treatment‐experienced, HIV‐1‐infected children and adolescents: 48‐week safety, efficacy and resistance analysis of the phase II PIANO study. HIV Medicine. 15(9). 513–524. 19 indexed citations
10.
Perri, Giovanni Di, Bruce Green, Glynn Morrish, et al.. (2013). Pharmacokinetics and Pharmacodynamics of Etravirine 400 mg Once Daily in Treatment-Naïve Patients. HIV Clinical Trials. 14(3). 92–98. 5 indexed citations
11.
Yéni, Patrick, Anthony Mills, Monika Peeters, et al.. (2010). Etravirine in the Treatment of HIV-1: A Clinical Overview for Healthcare Professionals. Current HIV Research. 8(7). 564–576. 2 indexed citations
12.
Kakuda, Thomas N., Monika Peeters, Chris Corbett, et al.. (2008). Pharmacokinetics (PK) and Pharmacodynamics (PD) of Etravirine (ETR) in Treatment-Experienced HIV-1 Infected Patients: Pooled 48-Week Results of DUET-1 and DUET-2. 46th Annual Meeting. 5 indexed citations
13.
Lalezari, Jacob, E DeJesus, Olayemi Osiyemi, et al.. (2008). O413 Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults. Journal of the International AIDS Society. 11(S1). 6 indexed citations
14.
Kakuda, Thomas N. & Monika Schöller‐Gyüre. (2008). Design of antiretroviral drug interaction studies. Current Opinion in HIV and AIDS. 3(3). 313–318. 1 indexed citations
15.
King, Jennifer R., et al.. (2007). Pharmacokinetics of Saquinavir With Atazanavir or Low‐Dose Ritonavir Administered Once Daily (ASPIRE I) or Twice Daily (ASPIRE II) in Seronegative Volunteers. The Journal of Clinical Pharmacology. 47(2). 201–208. 12 indexed citations
16.
Kakuda, Thomas N. & Jennifer J. Kiser. (2006). 7th International Workshop on Clinical Pharmacology of HIV Therapy. Expert Opinion on Pharmacotherapy. 7(11). 1519–1533. 20 indexed citations
17.
Kiser, Jennifer J., Peter L. Anderson, & Thomas N. Kakuda. (2006). 6th International Workshop on Clinical Pharmacology of HIV Therapy. Expert Opinion on Pharmacotherapy. 7(2). 229–241. 92 indexed citations
18.
Anderson, Peter L., et al.. (2004). The Cellular Pharmacology of Nucleoside‐ and Nucleotide‐Analogue Reverse‐Transcriptase Inhibitors and Its Relationship to Clinical Toxicities. Clinical Infectious Diseases. 38(5). 743–753. 110 indexed citations
19.
Anderson, Peter L., et al.. (2003). Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS. 17(15). 2159–2168. 117 indexed citations
20.
Kakuda, Thomas N., Linda M. Page, Peter L. Anderson, et al.. (2001). Pharmacological Basis for Concentration-Controlled Therapy with Zidovudine, Lamivudine, and Indinavir. Antimicrobial Agents and Chemotherapy. 45(1). 236–242. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jennifer J. Kiser Breakdown of academic impact, for papers by Brian P. Kearney Breakdown of academic impact, for papers by Sherene Min Breakdown of academic impact, for papers by Peter P. Koopmans Breakdown of academic impact, for papers by Ivy Song Breakdown of academic impact, for papers by Peter Ruane Breakdown of academic impact, for papers by Rolf P. G. van Heeswijk Breakdown of academic impact, for papers by Daniel Podzamczer Breakdown of academic impact, for papers by Pieter L. Meenhorst Breakdown of academic impact, for papers by Anne‐Marie Taburet
Rankless by CCL
2026